Reported Earlier, HUTCHMED Announces AstraZeneca Submitted US NDA For ORPATHYS Plus TAGRISSO In MET-Driven EGFR-Mutated NSCLC, Supported By Phase III SAFFRON Trial
HUTCHMED (China) Limited (HCM) Discusses Strategic Partnership With GSK and Licensing of Oncology Asset A830 - Slideshow (NASDAQ:HCM) 2026-09-07
Why Snowflake Shares Are Trading Higher By Over 24%; Here Are 20 Stocks Moving Premarket - Snowflake (NYS
AstraZeneca Reports Mixed Lung Cancer Trial Outcomes From Three Pivotal Studies - AstraZeneca (NYSE:AZN)